The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's arthritis drug, baricitinib, in combination with Gilead Sciences Inc's remdesivir, to treat COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback